GlassScriptPhysician profile
Earl K Wilson
NPI 1568455244
$16,601.20
in general payments reported to CMS, 2019-2025
67 companies · $2,576 in 2025
The $2,576 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,765 · 2020: $1,471 · 2021: $1,962 · 2022: $2,447 · 2023: $2,545 · 2024: $2,835 · 2025: $2,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,933 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,933.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,039.03 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $1,287.62 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Alexion Pharmaceuticals, INC. | $1,167.49 | 2019-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $914.63 | 2019-2025 | |
| Lilly USA, LLC | $808.54 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Neurelis, INC. | $664.95 | 2020-2025 | Valtoco |
| Mdd US Operations, LLC | $641.12 | 2019-2025 | Apokyn, Apokyn, Xadago |
| Biogen, INC. | $634.81 | 2019-2025 | Vumerity, Tysabri, Avonex |
| Lundbeck LLC | $533.23 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $489.70 | 2019-2025 | Austedo Xr, Austedo Xr |
| Allergan, INC. | $478.74 | 2019-2022 | |
| Genentech USA, INC. | $412.25 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Acadia Pharmaceuticals INC | $387.98 | 2019-2025 | Nuplazid |
| Eisai INC. | $375.50 | 2019-2025 | |
| Tg Therapeutics, INC. | $356.85 | 2024-2025 |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.